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PURPOSE. Geographic atrophy (GA) is a clinical phenotype of late age-related macular
degeneration (AMD) with no current treatment available. In this study, we investigated
markers of chronic inflammation in plasma of patients with GA and how these relate to
progression rate.
METHODS. We prospectively included 42 patients with GA, 41 patients with neovascular AMD,
and 27 healthy controls. We quantified levels of interleukin (IL)-1b, IL-6, IL-8, tumor necrosis
factor (TNF) receptor 2, and C-reactive protein (CRP). We adapted an inflammation summary
score to cluster conceptually related markers of chronic inflammation. Enlargement rate of
the atrophic lesion was measured from fundus autofluorescence images performed at baseline
and after 1 year.
RESULTS. Patients with GA showed an increase in proinflammatory markers of IL-6 (P ¼
0.009), TNF receptor 2 (P ¼ 0.013), and CRP (P ¼ 0.017) compared to healthy controls. We
found that IL-8 levels were markedly higher in patients with GA when compared to patients
with neovascular AMD (P ¼ 0.013). The inflammation summary score was high in patients
with neovascular AMD (P ¼ 0.024), but even higher in patients with GA (<0.001), when
compared to healthy controls. GA enlargement was measured in 36 patients, who completed
follow-up. Plasma levels of IL-6 had a moderate but significant correlation with GA
enlargement rate (R2 ¼ 0.23, P ¼ 0.0035).
CONCLUSIONS. Markers of chronic inflammation strongly associates with presence of GA
secondary to AMD. Plasma IL-6 possesses predictive ability of progression and constitutes the
first known plasma biomarker of disease activity in GA. These findings shed light into a poorly
understood clinical phenotype of AMD and highlights the important role of chronic
inflammation in GA.
Keywords: geographic atrophy, age-related macular degeneration, chronic inflammation,
inflammaging, interleukin 6
Age-related macular degeneration (AMD) is an acquireddisease of the macula, characterized by late-onset neuro-
degeneration of the photoreceptors and underlying retinal
pigment epithelium (RPE) cells.1 The earliest signs of AMD are
the presence of abnormalities and accumulation of lipoprotei-
naceous debris between the basal lamina of the RPE and the
underlying Bruch’s membrane.2 Features of late stage AMD
includes choroidal neovascularization (CNV) in which newly
formed vessels in the choroid protrude through the Bruch’s
membrane and into the retinal tissue, causing leakage and
destruction of photoreceptors. This subtype of late AMD,
neovascular AMD, is well-studied and treatment using inhibitors
of vessel formation (antibodies against vascular endothelial
growth factor) have significantly improved the clinical progno-
sis. Another prevalent, but poorly understood subtype of late
AMD is the atrophic form. Here, geographic atrophy (GA) is
described as demarcated areas of neuroretinal atrophy and of
the RPE that gradually progresses with time. The two late stages
are generally considered two distinct entities, although they
can occur in the same eye. Each year, 7% of patients with GA
develop CNV.3 Pure GA, without any CNV, accounts for
approximately 40% of cases with late AMD in the Caucasian
population.4 There are currently no treatment options for GA—
patients and doctors are bystanders in devastating gradual
destruction of the retina leading to impaired visual functioning
and life quality (Fig. 1).
GA growth takes place at very different rates among the
individuals affected. Studies of GA natural history find that: (1)
former progression rate predicts future rate; (2) rapid
progression in one eye tends to reflect in the other eye of an
individual affected bilaterally; (3) larger atrophic lesions
expands faster than smaller; (4) multifocal lesions grow faster
than unifocal lesions; (5) the finding of autofluorescent
accumulated lipofuscin patterns surrounding the atrophy
indicates accelerated progression.5 These clinical studies
provide insight into clinical progression. However, GA remains
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poorly understood from an etiological point of view and it
remains unknown what causes the disease and what sets the
progression rate.
Chronic low-grade inflammation is thought to play a central
role in AMD. Cross-sectional studies find higher levels of
proinflammatory markers in patients with neovascular AMD.6–8
This partly reflects an aging process—low-grade, nonsympto-
matic, sustained chronic inflammation is a well-documented
normal aging phenomenon, coined inflammaging,9 and an
acceleration of this process is thought explain why some
elderly are more likely to develop diseases where inflammation
play an important role. An imbalance between proinflamma-
tory and anti-inflammatory factors in the blood is not only
associated with AMD, but also several other age-related chronic
diseases, such as diabetes, cardiovascular diseases, and other
neurodegenerative disorders, such as Parkinson’s and Alz-
heimer’s disease.10 The etiology of chronic inflammation is not
fully understood, but is linked to a combination of persistent
activation of immune cells in chronic viral infections (e.g.,
cytomegalovirus),11 and a cellular senescence-induced trans-
formation of tissue microenvironment, into a senescence-
associated secretory phenotype releasing proinflammatory
cytokines, such as interleukin (IL)-6, tumor necrosis factor
(TNF)-a, IL-1b, and C-reactive protein (CRP).12,13
In this study, we investigated the relationship between
markers of chronic inflammation and GA secondary to AMD. In
a relatively large sample of 42 patients with pure GA without
any co-presence of CNV, we investigated association to plasma
markers of inflammation and whether these markers possess
any predictive ability to progression rate. We demonstrate, for
the first time, that a systemic biomarker positively and
significantly predicts GA progression rate. Our findings provide
a basis for future interventions in patients with GA that are
targeted chronic inflammation.
METHODS
Study Design
This was a prospective cohort study conducted at the
Department of Ophthalmology, Zealand University Hospital,
Denmark. We included patients with pure GA from the retinal
clinic. As control group we included patients with neovascular
AMD and patients’ spouses accompanying them in the clinic
were invited to participate as healthy controls.
Study Participants and Inclusion
The content, rationale, and purpose of the study was explained
to all participants. Oral and written informed consent was
obtained prior to inclusion. The study followed the tenets of
the Declaration of Helsinki and was approved by the Regional
Ethics Committee (reference number: SJ-385).
All participants were subjected to a structured interview
and questioned about medical history, current medication use,
tobacco, and alcohol consumption. Physical activity was
assessed using a single-sentence question previously validated
in patients with AMD.14,15 Height and weight was used to
calculate body mass index.
Inclusion Criteria. GA secondary to AMD, neovascular
AMD, or no retinal disease.
Exclusion Criteria. Any other retinal disease than AMD,
optic opacities (e.g., cataract), acute inflammatory or infec-
tious disease, cancer, or use of any immune modulating
medication (e.g., methotrexate, steroids in any form).
Participants were excluded post hoc in cases of CRP above
15 mg/L, due to suspected acute inflammation.16
Retinal Examination and Definition of GA
Trained specialist performed comprehensive ocular examina-
tion in all cases to secure diagnosis. This examination included
best-corrected visual acuity, slit-lamp biomicroscopy, digital
fundus photography, spectral-domain optical coherence to-
mography, and fundus autofluorescence (FAF) imaging. Retinal
angiography using fluorescein and indocyanine green was
performed in cases with suspected neovascularization.
GA was defined as one or more well-defined areas of
depigmentation of the RPE, corresponding to reduced FAF
signal, in an eye with pigmentary abnormalities and soft or
reticular drusen.17 Patients were not included if they had any
signs of active or former CNV in any eye or other retinal
disease.
Healthy controls had <10 small drusen (<63 lm in size),
which are regarded as normal aging changes, and no RPE
abnormalities in either eye.17
Patients with neovascular AMD had fibro-vascular detach-
ments of the RPE and choroidal neovascular membranes with
subretinal or sub-RPE hemorrhages or fibrosis, in one or both
eyes. Patients with neovascular AMD were included regardless
of any co-existence of atrophic regions in either eye.
Image Processing and Grading
Each image was evaluated by two individual investigators
(MKN and MKF) blinded from any demographic or clinical
information. Delineation of the atrophic area was performed
using RegionFinder software version 2.5.7.0 (Heidelberg
Engineering, Heidelberg, Germany). The readers manually
selected the darkest area of the atrophic lesion (pixels with
the lowest signal), and increased the threshold to include
adjacent pixels, until the area marked corresponded to the
lesion boundaries. In cases of multifocal lesions, all lesions
‡0.05 mm2 were measured and included in the total lesion
size. Manually placed constraints were used to exclude
vessels or macula pigment from the GA delineation.18
Examples of GA progression and delineation are demonstrat-
ed in Figure 1.
FIGURE 1. Examples of atrophy enlargement over 1 year in patients
with GA secondary to AMD based on FAF image. Each case is presented
horizontally with baseline FAF image (left), follow-up FAF image
(middle), and progression area outlined on baseline-image (right). Top:
right eye of an 86-year-old man with 7.4 mm2 unifocal lesion.
Progression rate was 1.2 mm2 in 1 year. Bottom: right eye of 80-year-
old woman with 3.2 mm2 multifocal lesion. Progression rate was 2.0
mm2 in 1 year.
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Blood Sampling, Genotyping, and Cytokine Assays
Venous blood was sampled from the antecubital vein. Tubes
coated with ethylenediamine-tetraacetic acid were posted to
the Kennedy Center (Glostrup, Denmark) for extraction of
genomic DNA using Chemagic Magnetic Separation Module 1
(Chemagen, Baesweiler, Germany). DNA samples were sent for
genotyping at LGC Genomics Ltd (Herts, UK) where genotyp-
ing was performed using in-house KASP (kompetitive allele
specific polymerase chain reaction) genotyping SNP-line
system. The following SNPs were analyzed: CFH rs1061170
and ARMS2 rs10490924.
Two lithium-heparin coated blood filled tubes were used for
cytokine assays. One tube was used for determining CRP using
Dimension Vista 1500 (Siemens Healthineers, Erlangen, Ger-
many). Another tube with lithium heparin stabilized blood was
centrifuged for 15 minutes at 1500g, after which plasma was
immediately isolated and stored at 808C. Plasma concentra-
tion of inflammatory biomarkers were measured at initial visit.
We quantified plasma levels of IL-1b, IL-6, IL-8, IL-10, and TNF-
receptor 2 (TNF-R2). Instead of measuring the labile TNF-a, we
measured the soluble TNF-R2, which has a longer half-life, and
therefore is a more stable indicator of the average TNF-a
level.19 Cytokines were quantified using commercially available
multiplex immunoassays (Meso Scale Discovery, Gaithersburg,
MD, USA), and plates were prepared according to the
manufacturer’s instructions. Reading was done immediately
after plate preparation on QuickPlex SQ120 (Meso Scale
Discovery). All tests were run in duplicate and done randomly
across plates. We included a standard on each plate to provide
an eight-point standard curve, which was created using the
manufacturer’s software, by plotting the mean absorbance
against the protein concentration. The concentration of target
protein in each sample was automatically determined based on
the standard curve. The coefficient of variation was calculated
as the ratio of the standard deviation to the mean. We
calculated the coefficient of variance (CV) in each sample,
defined as the ratio of the standard deviation to the mean. Tests
were included if the duplicates were within 20% of the mean,
otherwise they were repeated. Quality of the cytokine assays
were satisfactory (CV in % of mean 6 SD of the individual
cytokine: IL-1b: 6.5 6 7.6; IL-6: 4.9 6 4.1; IL-8: 2.9 6 2.6; IL-
10: 4.7 6 4.1; TNF-R2: 8.9 6 5.6).
Data Analysis and Statistics
For each patient we measured the atrophic area, and we
repeated the measurement after 12 months. Interrater agree-
ment between the two graders was assessed by calculating the
interclass correlation coefficient. Due to the systemic mea-
surements, and their supposed influence on both eyes, we only
included one eye per patient to perform independent
sampling.20 In cases of bilateral GA, the right eye was included.
To reflect the general systemic inflammatory state, we
adapted a summary score for low-grade inflammation to cluster
conceptually related markers of low-grade inflammation. The
index was developed to evaluate effect of lifestyle changes in
chronic inflammation.21 Since the markers are expressed on
different scale units, a z score for each marker was calculated.
Subsequently these z scores were averaged to obtain a
summary score for each participant:
Summary score ¼ z score logeCRPð Þ þ z score logeIL  6ð Þ½
þ z score logeIL  8ð Þ
þ z score LogeTNF  R2ð Þ=4
To evaluate the size of the observed differences in this
adapted score, we calculated Cohen’s d, defined as the ratio
between the group difference and the SD. We interpreted the
effect size as suggested by Cohen (0.2: small; 0.5: moderate;
0.8: large).22
Statistical analyses were made using SPSS 24 (IBM Corpo-
ration, Armonk, NY, USA). Categorical data are presented with
numbers and percentages, and compared using v2 test, unless
sample size is small (expected count  5), in which case we
used Fischer’s exact test. Continuous data were tested for
normal distribution visually by histograms and by using the
one-sample Kolmogorov-Smirnov test. When normal distribu-
tion was present, data were presented as mean and SD, and
comparisons were made using a 1-way ANOVA or independent
samples t-test. When data were not normally distributed, it was
presented with median and interquartile range (IQR) and
compared using the nonparametrical Mann-Whitney U test or
Kruskal-Wallis test.
For each patient we calculated the change in total GA lesion
area in 1 year. To report progression rate normalized for
baseline lesion size, we applied the square root transformation
strategy. This mathematical method serves to eliminate the
dependence on baseline lesion size for the growth rates.23–25
The evaluation of association between plasma markers and
enlargement rate of GA was performed using a linear
regression analysis.
RESULTS
Participants
A total of 118 participants were included, of which eight were
excluded post hoc. Seven patients with GA were excluded due
to following events during the follow-up period: Five patients
were excluded due to development of CNV, one was excluded
due to retinal vein occlusion, and two were excluded due to
diagnosis of cancer in the follow-up period. One patient with
neovascular AMD was excluded due to CRP of 18 mg/L. None
of the 27 healthy controls were excluded. The three groups
were compared on demographic and clinical parameters, and
did not differ significantly, as presented in Table 1. Patients
with GA were slightly elder than the others. Our impression is
that more of the younger patients had a spouse, serving as
healthy control, than the very old patients, since they were
more frequently widowed. Patients with late stage AMD—both
neovascular AMD and GA—had a higher occurrence of the
AMD-associated genetic risk variants of CFH and ARMS2. None
of the SNPs deviated from Hardy-Weinberg equilibrium
(rs1061170, v2 ¼ 1.0209, P ¼ 0.5962; rs10490924, v2 ¼
0.0297, P ¼ 0.5962).
Group Comparisons
We found that all AMD patients had significantly increased
levels of IL-6, IL-10, TNF-R2, and CRP (Table 2). When
comparing GA to neovascular AMD, we found a marked
difference in levels of IL-8, which were solely increased in
patients with GA. The calculated inflammation summary
scores were significantly elevated in both groups of patients
compared to healthy controls, but patients with GA had a
significantly higher score than patients with neovascular AMD
(Table 2). The difference in summary scores between patients
with neovascular AMD and healthy controls had a moderate
size (Cohen’s d: 0.60), whereas the difference between
patients with GA and healthy controls had a large size (Cohen’s
d: 1.14). The difference in between patients with GA and
patients with neovascular AMD had a moderate size (Cohen’s
d: 0.50).22
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Due to the tendency of patients with GA being slightly older
than other study groups and composed of more females, we
investigated if measured cytokine levels correlate with age or
gender. We found that the relationship with age was weak and
insignificant (all correlations had rho < 0.3 and P > 0.2) and
found no evidence of any differences between males and
females (P > 0.1).
Progression of Atrophic Lesion Area
Thirty-six of the included GA patients completed follow-up.
One patient died of cardiovascular event, one patient
developed severe dementia, and three patients did not provide
cause of absence. The mean follow-up time was 12.7 months
(range, 12–17 months). Interrater agreement of lesion area
measurement between the two graders had an interclass
correlation coefficient of 0.90, which indicates excellent
agreement. The median enlargement rate of the atrophic
lesion was 1.6 mm2 per year (range, 0.1–4.3 mm2 per year).
Progression of GA in the study eye correlated significantly with
progression rate in the fellow eye (rho: 0.64; P < 0.001).
Do Markers of Inflammation Predict Progression
Rate of GA?
We used linear regression analysis to test the predictive ability
of the markers of inflammation and the progression rate of GA
over 1 year. Plasma IL-6 moderately and significantly predicted
TABLE 1. Baseline Characteristics of Participants
GA (n ¼ 42) Healthy (n ¼ 27) nAMD (n ¼ 41) P
Age, median (IQR) 80.5 (74.0–87.0) 76.0 (72.0–82.0) 77.0 (72.0–81.0) 0.060*
Female, n (%) 28 (66.7) 13 (48.1) 22 (53.7) 0.266†
Body mass index, mean (SD) 26.4 (5.6) 25.7 (3.6) 26.2 (4.1) 0.880‡
Hypertension, n (%) 25 (59.5) 9 (33.3) 21 (51.2) 0.103†
Hypercholesterolemia, n (%) 15 (35.7) 9 (33.3) 11 (26.8) 0.673†
Cardiovascular disease, n (%) 15 (35.7) 4 (14.8) 11 (26.8) 0.163†
Type 2 diabetes, n (%) 5 (11.9) 0 (0) 5 (12.2) 0.167†
Smoking habits, n (%) 0.239†
Current 9 (21.4) 2 (7.4) 12 (20.9)
Former 17 (40.5) 13 (48.1) 18 (43.9)
Never 16 (38.1) 18 (43.9) 11 (26.8)
Alcohol consumption, median (IQR) 3.0 (1.0–7.0) 5.0 (2.5–7.0) 3.0 (0.5–8.0) 0.398*
Daily exercise, n (%) 27 (64.3) 18 (66.7) 21 (51.2) 0.343†
CFH genotype,§ n (%) 0.183†
C:C 11 (26.2) 3 (11.1) 13 (31.7)
C:T 23 (54.8) 15 (55.6) 17 (41.5)
T:T 7 (16.7) 8 (29.6) 5 (12.2)
ARMS2 genotype,§ n (%) 0.003†
T:T 9 (21.4) 2 (7.4) 12 (20.9)
T:G 17 (40.5) 13 (48.1) 18 (43.9)
G:G 16 (38.1) 18 (43.9) 11 (26.8)
nAMD, neovascular AMD.
* Kruskal-Wallis test.
† v2 test.
‡ One-way ANOVA.
§ Seven analyses failed in CFH genotyping and five analyses failed in ARMS2 genotyping.
TABLE 2. Plasma Levels of Inflammatory Markers Differed Between Patient Groups
GA (n ¼ 42) Healthy (n ¼ 27) nAMD (n ¼ 41)
P
GA vs.
Healthy
GA vs.
nAMD
nAMD vs.
Healthy
IL-1b pg/mL, median (IQR; range)* 0.3 (0.2–0.4; 0.7) 0.3 (0.2–0.5; 1.2) 0.3 (0.2–0.5; 2.3) 0.519 0.670 0.755
IL-6 pg/mL, median (IQR; range)* 2.2 (1.7–3.1; 5.0) 1.5 (1.2–2.4; 5.6) 2.6 (1.5–3.9; 4.9) 0.009 0.600 0.024
IL-8 pg/mL, median (IQR; range)* 6.6 (4.1–11.7; 56.9) 4.7 (3.7–8.0; 20.7) 4.8 (3.6–7.0; 21.1) 0.085 0.013 0.535
IL-10 pg/mL, median (IQR; range)* 0.6 (0.5–0.9; 1.6) 0.5 (0.4–0.7; 0.9) 0.8 (0.6–1.2; 1.8) 0.052 0.087 0.002
TNF-R2 ng/mL, median (IQR; range)* 6.6 (5.3–8.7; 19.9) 5.4 (3.9–6.8; 8.0) 5.7 (4.0–7.5; 9.7) 0.013 0.096 0.370
CRP mg/L, n (%)† 0.017 0.814 0.058
0–2.9 24 (57.1) 21 (88.9) 26 (73.5)
3.0–9.9 15 (35.7) 3 (11.1) 13 (31.7)
10–15 3 (7.1) 0 (0) 2 (4.9)
Inflammation summary score,‡ mean (SD)§ 0.27 (0.64) 0.34 (0.40) 0.04 (0.59) <0.001 0.024 0.016
nAMD, neovascular AMD.
* Mann-Whitney U test.
† v2 test.
‡ Inflammation summary score ¼ [ z score (logeCRP) þ z score (logeIL-6) þ z score(logeIL-8) þ z score(LogeTNF-R2)] / 4.
§ Unpaired t-test.
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the progression rate of GA (R2 ¼ 0.23, P ¼ 0.0035) (Fig. 2),
whereas the other markers did not possess any predictive
ability (all P > 0.05). The inflammation summary score
possessed a weak trend of predictive ability of the progression
rate (R2 ¼ 0.09, P ¼ 0.087) (Fig. 2).
DISCUSSION
In this study, patients with GA had distinctly elevated levels of
plasma IL-6, IL-8, TNF-R2, and CRP. When comparing the
adapted inflammation summary score, we found this increased
in patients with GA compared to patients with neovascular
AMD. The increase in IL-8 differs from patients with
neovascular AMD, who displayed levels similar to that of
healthy controls. GA enlargement rates were associated
significantly with patient plasma level of IL-6.
We find a median enlargement rate of 1.60 mm2 per year in
the study eye, and very similar rate in fellow eyes. This is in line
with previous observational studies on GA enlargement in
which progression rates range from a median of 0.53 to 2.6
mm2/year. A recent review by Fleckenstein et al.5 synthesized
the literature on GA natural history and found a median
enlargement rate of 1.78 mm2/year. In line with previous
observation studies, we also found a strong association
between intereye progression rates in patients with bilateral
GA.5
The role of systemic inflammation in brain and retinal aging
has received increasing attention, since prolonged systemic
inflammation can induce neuroinflammatory changes, and
subsequently neurodegeneration. The effect of systemic
inflammation to exacerbate or even drive neuronal dysfunction
is described in Alzheimer’s disease, but also in nonsympto-
matic elderly individuals.26,27 Plasma levels of inflammatory
markers, such as CRP, is associated with risk of AMD, but if it
serves as a biomarker, or if there is a causal association is
unknown. The latter is indicated by research demonstrating
that CRP, IL-6, IL-8, and TNF-a have direct impact on RPE cells
and choroidal endothelial cells in vivo.28–30
The cellular effect of IL-6 works through two distinct
pathways. The classical, anti-inflammatory pathway works
through stimulation of membrane-bound IL-6-receptor (IL-6R).
The IL-6R initiates dimerization of gp130 and subsequent
downstream signaling, leading to activation of selective cells,
among these microglia cells, which is appropriate in pathogen-
defense response.31 The alternative activation pathway is
through formation of a complex with the soluble IL6-receptor
(sIL-6R), which is released from na¨ıve T cells as they
differentiate. This complex stimulates cells that express
gp130 but not surface-bound IL-6R, and therefore are not
sensitive to IL-6 in itself. Gp130 is expressed on numerous
cells, including glia cells and neurons, explaining the wide-
spread effect of chronic IL-6 elevation. The IL6-sIL6R complex
formation and stimulation is termed trans-signaling.32
The special relevance of IL-6 in neuroinflammation is due to
the fact that increased levels of IL-6 mediates the increased
surface expression of the cell adhesion molecule vascular cell
adhesion protein-1. This process disrupts the integrity of the
blood-brain-barrier, and allows IL-6, along with other immune
cells, to traverse the endothelial layer.33 Elevated levels of IL-6
in the brain and periphery, can form a feed-back activation
loop, as trans-signaling promotes differentiation of na¨ıve T cells
into the pathogenic Th17 cell, and in this differentiation gives
rise to more IL-6 and sIL-6R.33,34
Mononuclear phagocytes (microglia and blood-derived
macrophages) are thought to play a central role in GA as they
are found accumulated within the atrophic area of donor
eyes.35,36 These cells change in phenotype according to the
surrounding microenvironment. A proinflammatory environ-
ment promotes differentiation into the inflammatory M1
phenotype, contributing further to inflammation, and initiation
of an adaptive immune response.37 An individual’s capacity to
generate and maintain an inflammatory response varies greatly,
and the difference is, to a large extent, determined by genetic
factors. In AMD, there is a strong genetic component, and a
number of studies have highlighted ARMS2 and CFH as the
major susceptibility loci of AMD.38,39
In particular, the CFH at-risk CC variant results in an
increased activation of the complement cascade and has been
associated with a higher risk of AMD development and
progression to late-stage AMD.40,41 The ARMS2 gene codes
for the age-related maculopathy susceptibility protein, whose
functions has to be yet clarified. The ARMS2 at-risk TT variant
increases the risk of developing AMD by 7.6-fold compared to
heterozygotes. The presence of risk variants has been further
linked to increased levels of CRP in the at-risk TT variants in
subjects with no evidence of AMD.42 This relationship between
CRP and ARMS2 risk variants suggests the potential role of
gene polymorphisms in inflammation and AMD susceptibility.
In the present study, we find that AMD patients have a higher
occurrence of the AMD-associated genetic risk variants. This is
in line with findings of large genotype studies of such
patients,40–42 which indicates that our study group can be
FIGURE 2. (A) Plasma IL-6 positively predicts future progression rate of the atrophic lesion in patients with GA. The progression rate is normalized
for baseline area using square root transformation (SQRT). (B) The predictive ability of IL-6 is superior to the inflammation summary score. This
score is calculated based on the proinflammatory markers (IL-6, IL-8, TNF-receptor 2, CRP).
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considered a representative sample of patients with late stage
AMD.
Blockage of IL-6 has shown to alleviate NLRP3 inflamma-
some,43 presumably due to IL-6’s ability to promote IL-17A.44
IL17A has been shown to induce IL-1b secretion from RPE cells
via the NLRP inflammasome,45 indicating a possible effect of IL-
6 in a harmful inflammatory feedback circle. Therefore, we
suggest a local feedback system generates a microenvironment
of inflammation and cell death that is induced by persistent
systemic IL-6 trans-signaling. This would explain why the
association of systemic IL-6 and GA enlargement appear when
the progression rate is normalized for the baseline lesion size,
via the square root transformation.
In this study, we found a marked increase of plasma IL-8 in
patients with GA, a finding that was not shared in patients with
neovascular AMD. Besides serving as a marker of inflammation,
IL-8 is part of the chemokine family. Chemokines are
constitutively expressed in the organism and the brain. IL-8 is
secreted by neutrophils, monocytes, macrophages, and endo-
thelial cells. IL-8 function includes cell adhesion, recruitment
of neutrophils and lymphocytes to sites of inflammation. In the
CNS both neurons and glia cells produce IL-8.46 Expression of
IL-8 is increased in retinal microglia activation,47 and in RPE
cells when they are exposed to T cell-derived proinflammatory
cytokine TNF-a.48 IL-8 receptor CXCR2 has been shown to
regulate T-cell migration and patients with Alzheimer’s disease
has increased expression of CXCR2, to enhance the trans-
endothelial migration. In a blood-brain barrier model, T-cell
migration was blocked through anti-CXCR2 antibody or IL-8
RNA interference.49 In patients with Alzheimer’s disease,
plasma IL-8 is linked to presence and severity of disease. It is
possible that GA holds similarities with patients with
Alzheimer’s, in terms of cell migration prior to neurodegener-
ation, but this theory needs further studies to explore.
The roles of IL-6 and IL-8 are extremely diverse in the
human organism, as it is produced by various cell types and
have many effector sites. Persistent low-level IL-6 is associated
with many age-related degenerative diseases.50 Therefore, the
exact role of IL-6 in GA progression needs to be elucidated. In
the case, that IL-6 holds a causal role in GA enlargement, this
opens possibilities to intervene in a disease, that is common,
disabling, and currently has no treatment option. Due to its
many influences in the body, IL-6 interventions are thoroughly
studied. One strategy to halter the harmful effect of trans-
signaling is use of the physiological soluble form of gp130,
which has been successful in blocking trans-signaling and
reduce neuropathological changes in mice, without haltering
the classical beneficial IL-6 signaling.51,52
Important limitations should be kept in mind when
interpreting these results. First, due to the observational
nature of the study, we can only speculate on causality.
Furthermore, the study sample size does not allow for
subgroup analysis in GA patients. Previous studies have
stratified eyes with GA into subtypes based on autofluores-
cence patterns, and knowledge on inflammatory levels in these
subgroups might provide further insight into the pathogenesis
of this poorly understood subtype of AMD.
In conclusion, we find that GA is associated with chronic
inflammation. Patients with GA differs from patients with
neovascular AMD in their vastly higher plasma levels of IL-8,
suggesting a distinct inflammation profile. We demonstrate that
a high level of plasma IL-6 is associated with a fast progression
profile. Assessment of chronic inflammation may add signifi-
cant information to the evaluation of the risk of GA and
prediction of rates of disease progression over time. Future
studies need to evaluate clinical efficacy of targeting chronic
inflammation in GA.
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